Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer
Therapeutic Advances in Medical Oncology · 2026-11 · 18
DOI: 10.1177/17588359261504792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 19.11.2026. Verfasst von Shidi Zhao und 14 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shaanxi Province, Beijing Kechuang Medical Development Foundation, Beijing Oasis of Life Public Welfare Service Center.
Abstract (Originalsprache)
Background
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have significantly improved outcomes for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC). However, the most effective treatment strategies after CDK4/6i progression remain unclear in real-world clinical practice.
Objectives
This multicenter study aimed to characterize real-world treatment patterns and outcomes among patients with HR+/HER2- MBC treated with CDK4/6i in northwest China and to explore subsequent treatment strategies after CDK4/6i progression.
Design
This was a multicenter retrospective cohort study conducted across 11 hospitals in northwest China. Real-world treatment patterns and outcomes before and after CDK4/6i progression were evaluated.
Methods
Patients with HR+/HER2- MBC who received CDK4/6i for the first time between July 2017 and December 2024 at 11 centers were retrospectively included. The objective response rate (ORR), real-world progression-free survival (rwPFS) achieved by CDK4/6i, and outcomes of post-CDK4/6i treatments were analyzed. Survival outcomes were estimated using Kaplan–Meier methods and compared using the log-rank test.
Results
A total of 605 patients were screened, and 592 were included in the final analysis, including 398 (67.2%), 126 (21.3%), and 68 (11.5%) who received CDK4/6i therapy as first-, second-, and third- or later-line treatment, respectively. The median rwPFSa was 22.9 months (95% CI 19.6-26.7 months). Earlier initiation of CDK4/6i was associated with longer median rwPFSa (first-line 26.6 vs second-line 21.0 vs later-line 11.0 months, P =0.00014). Data on at least two consecutive treatment lines after CDK4/6i progression were available for 225 patients. The first post-CDK4/6i regimen was chemotherapy (CT), endocrine therapy-based (ET-based) therapy, or antibody–drug conjugates (ADC) in 121 (53.8%), 88 (39.1%), and 16 (7.1%) patients, respectively. In the unadjusted analysis, median rwPFSb differed among the three groups (CT 5.67 vs ET-based therapy 9.20 vs ADC 10.03 months; overall log-rank P = 0.00029). After multivariable adjustment, CT remained associated with shorter rwPFSb than ET-based therapy (adjusted HR = 1.736, 95% CI 1.253–2.405; P < 0.001), whereas ADC was not significantly different from ET-based therapy (adjusted HR = 0.804, 95% CI 0.383–1.689; P = 0.565). In an unadjusted exploratory analysis, median rwPFS3 differed among the CDK4/6i→ET-based therapy→ET-based therapy, CDK4/6i→ET-based therapy→CT, and CDK4/6i→ET-based therapy→ADC (32.93, 23.53, and 33.67 months, respectively; overall log-rank P = 0.0017).
Conclusions
Our real-world findings support early initiation of CDK4/6i plus ET in patients with HR+/HER2− MBC. Earlier initiation of CDK4/6i plus ET was associated with longer rwPFSa. After CDK4/6i progression, CT was associated with shorter rwPFSb than ET-based therapy after multivariable adjustment, whereas ADC was not significantly different from ET-based therapy. Residual confounding and the exploratory nature of the unadjusted treatment-sequence analyses preclude conclusions regarding an optimal treatment order.
Förderung
- Natural Science Foundation of Shaanxi Province
- Beijing Kechuang Medical Development Foundation
- Beijing Oasis of Life Public Welfare Service Center
Zitieren
APA
Zhao, S., Zhao, J., Song, B., Tian, Y., Ling, X., Li, D., Li, X., Jia, H., Yang, X., Xue, Y., Bai, X., Dong, D., Liu, X., Yang, J., & Yang, J. (2026). Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261504792
Vancouver
Zhao S, Zhao J, Song B, Tian Y, Ling X, Li D, et al. Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261504792
BibTeX
@article{Zhao2026,
author = {Zhao, Shidi and Zhao, Jiuda and Song, Bin and Tian, Yingxia and Ling, Xiaoling and Li, Donghui and Li, Xinzheng and Jia, Hongyan and Yang, Xuan and Xue, Yan and Bai, Xiaorong and Dong, Danfeng and Liu, Xinlan and Yang, Jin and Yang, Jiao},
title = {Real-world treatment patterns and outcomes during and after treatment with CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261504792}
}
EUVIMED